HONG KONG, July 30, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific antibody) in combination with docetaxel for the...
Hence then, the article about akeso announces completion of first dosing in phase iii clinical trial of ivonescimab pd 1 vegf combination therapy for immunotherapy resistant nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC )
Also on site :
- UN renews Sudan ceasefire appeal over ‘unimaginable suffering’ of civilians
- The Supreme Court Cast Its Lot With Trumpism. It Should Be Very Worried.
- Central African Republic election: Who’s running and what’s at stake?